Make your voice heard—urge Congress and the FDA to preserve access to compounded GLP-1 treatments.
I am writing to express my concern about the potential loss of access to compounded GLP-1 treatments, which hundreds of thousands of Americans have found to be essential for managing their health.
Due to affordability and availability issues, patients have relied on compounded GLP-1/GIP through Morph as an alternative to the brand-name medications from Eli Lilly and Novo Nordisk. If the FDA moves forward with restricting compounded GLP-1s, patients will be faced with the difficult choice of either spending significantly more money on name-brand products or forgoing a treatment that has been life-changing.
Compounded GLP-1s are not just an alternative—they are essential medications for patients who rely on them to manage their health safely and effectively. Restricting access to compounded GLP-1s would undermine the health of patients who have no other viable options.
I ask you to consider the real, life-changing impact of these treatments. Please ensure that patients continue to have access to compounded GLP-1s as a critical part of health management. I hope that the administration listens to the voices of those who support and depend on this medication.
Thank you for your attention to this matter.
From June 22 to June 28, Morph Health and Wellness will be undergoing a patient portal transition, which will adjust appointment booking flow.
All appointments booked in Boulevard during this window of time will be automatically re-booked into the new patient portal system, EMRG.
This will not alter your selected appointment time or chosen provider; it only helps you avoid having to complete a second set of forms and upload information in a different portal right after registering as a patient with us!
We aim to make this transition as easy as possible for you! Please direct any questions to our team at 770-243-5753 or contact@elevismed.com.
